Compare BIO-TECHNE Corp (TECH) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Short Term Corporate Bond ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Short Term Corporate Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VCSH | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Fixed Income |
52-Week High | $72.29 | $80.20 |
52-Week Low | $43.31 | $78.41 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VCSH trades at $78.61, up 0.17% with neutral technical signals. The ETF offers a short 2.7-year duration and a 4.77% yield, attracting income-focused investors amid stable rate expectations. Recent institutional activity shows mixed positioning, with some firms reducing stakes while others increase holdings. Credit spreads remain tight, limiting near-term upside potential but providing downside protection.
Outlook is cautious due to unattractive entry points and tight spreads. The ETF suits conservative portfolios seeking steady income with low volatility, though limited rate cuts in 2026 may cap gains. Risks include credit spread widening and competition from higher-yielding alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
